2026-01-102026-01-102023-09-30https://repos.sumathipublications.com:8000/handle/123456789/264ABSTRACT In the realm of cardiovascular protection, aspirin emerges as a potent sentinel against Coronary Artery Disease (CAD). Beyond its well-known pain-relief properties, aspirin's remarkable antiplatelet action takes center stage. By inhibiting platelet aggregation through COX-1 enzyme suppression, aspirin mitigates the formation of arterial thrombi, crucial in averting heart attacks and strokes. Aspirin's role spans both secondary and selective primary prevention. In secondary prevention, it stands as a stalwart defense, substantially lowering the risk of recurrent cardiovascular events. In primary prevention, its application is tailored to high-risk individuals, although careful consideration of bleeding risks is paramount. Yet, aspirin is not immune to scrutiny. Concerns include potential bleeding complications, gastric irritation, and drug interactions. In this evolving landscape, its application aligns with emerging guidelines, fine-tuning its role in CAD management. "Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease" encapsulates aspirin's pivotal stance in cardiovascular protection. As a guardian of platelet activity, it plays a crucial role in curbing CAD's impact, symbolizing hope in the battle for heart health. Keywords: Coronary artery disease, Heart, Management.application/pdfCopyright (c) 2023 Abrar Bashir Malik, Mashooq Ahmad Mir, Zulfkar Qadrie, Mohd Altaf Darhttp://creativecommons.org/licenses/by-nc-sa/4.0Coronary artery diseaseHeartManagementinfo:eu-repo/semantics/article